Sotagliflozin

索格列净

Report date: 2026/05/20 20:02:01
NMEFirst In Class

Base Information

Drug NameSotagliflozin
Drug Alias NamesotagliflozinasotagliflozinumsotagliflozineZynquistaINPEFA +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 1 inhibitorsSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2Sodium/glucose cotransporter 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus +[15] 
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Heart Failure +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2019/04/26
Country/TerritoryCzechiaBelgiumBulgaria +[50] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesSanofiLexicon Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbott LaboratoriesOregon Health And Science UniversityOxford Finance LLC +[11] 
Inactive CompaniesGuidehouse Germany GmbHSanofiSanofi-Aventis Recherche & Developpement +[5] 
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus +[11] 
Inactive IndicationsCardiovascular DiseasesRenal InsufficiencyKidney Diseases +[4] 

Other Information

ATC CodeA10BK06
Related LinksKEGG